Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
dorzolamide timolol · 2 trials · 2 indications
Change from baseline to 8 weeks in Intraocular Pressure (IOP) assessed 2 hours after ocular instillation (at Hour 2)
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | combination of dorzolamide hydrochloride and timolol maleate |
| 2 | ACTIVE_COMPARATOR | Concomitant use of dorzolamide hydrochloride and timolol maleate |
| 3 | ACTIVE_COMPARATOR | timolol maleate |
| Name | Type | Description |
|---|---|---|
| dorzolamide hydrochloride (+) timolol maleate | DRUG | Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week |
| Comparator: timolol maleate | DRUG | timolol maleate 0.5%, 8-week |
| Comparator: dorzolamide hydrochloride | DRUG | dorzolamide hydrochloride 1%, 8-week |
| Comparator: dorzolamide HCl/timolol maleate + prostaglandin | DRUG | Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension. For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks. |
Inclusion Criteria: * Patients with glaucoma and ocular hypertension Exclusion Criteria: * History of ocular surgery within 3 months * Administration contradiction to timolol and dorzolamide
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Timolol eye 0.5% |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | Undisclosed |
| SpyGlass Pharma, Inc. | SGP | 4 | PHASE3 | Bimatoprost System, Timolol, 0.5% |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 2 | PHASE3 | Test- Bimatoprost 0.01%, Reference- LUMIGAN |
| Alcon AG | ALC | 5 | N/A | Undisclosed |
| Sight Sciences, Inc. | SGHT | 3 | N/A | Undisclosed |
Dorzolamide timolol is used for glaucoma, including ocular hypertension. It is a small molecule being developed by Merck & Company, Inc. for the treatment of these eye conditions. The drug is currently in Phase 3 clinical development, with completed trials evaluating its effectiveness in patients with glaucoma and ocular hypertension.
Dorzolamide timolol is a combination of two active ingredients: dorzolamide, a carbonic anhydrase inhibitor, and timolol, a beta-blocker. Together, they work to reduce intraocular pressure in patients with glaucoma and ocular hypertension by decreasing the production of fluid in the eye.
Dorzolamide timolol is developed by Merck & Company, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol MRK. The drug is being studied for the treatment of glaucoma and ocular hypertension.
Dorzolamide timolol is in Phase 3 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory authorities. Two Phase 3 trials have been completed, with a total of 644 patients enrolled, but the drug remains under investigation.
Dorzolamide timolol has completed two Phase 3 clinical trials. The first, NCT00449956, enrolled 474 patients with glaucoma. The second, NCT00546286, enrolled 170 patients with glaucoma and ocular hypertension. Both trials were randomized, double-blind, and controlled, and have been completed.
Dorzolamide timolol is the same as Cosopt, as indicated by the clinical trial NCT00546286, which evaluates the effectiveness of Cosopt as first-line therapy. Cosopt is a brand name for the combination of dorzolamide and timolol, used to treat glaucoma and ocular hypertension.